HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells
Amin, Dhara N, Sergina, Natalia, Lim, Lionel, Goga, Andrei, Moasser, Mark M
Published in Biochemical journal (01.11.2012)
Published in Biochemical journal (01.11.2012)
Get more information
Journal Article
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver
Amin, Dhara N, Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Blair, Jimmy A, Wang, Donghui, Hann, Byron, Koch, Kevin M, Shokat, Kevan M, Moasser, Mark M
Published in Science translational medicine (27.01.2010)
Published in Science translational medicine (27.01.2010)
Get more information
Journal Article
Disentangling multidimensional spatio-temporal data into their common and aberrant responses
Chang, Young Hwan, Korkola, James, Amin, Dhara N, Moasser, Mark M, Carmena, Jose M, Gray, Joe W, Tomlin, Claire J
Published in PloS one (22.04.2015)
Published in PloS one (22.04.2015)
Get full text
Journal Article
A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers
Amin, Dhara N, Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M
Published in Molecular cancer therapeutics (01.12.2015)
Published in Molecular cancer therapeutics (01.12.2015)
Get full text
Journal Article
Tumor-associated endothelial cells with cytogenetic abnormalities
HIDA, Kyoko, HIDA, Yasuhiro, AMIN, Dhara N, FLINT, Alan F, PANIGRAHY, Dipak, MORTON, Cynthia C, KLAGSBRUN, Michael
Published in Cancer research (Chicago, Ill.) (15.11.2004)
Published in Cancer research (Chicago, Ill.) (15.11.2004)
Get full text
Journal Article
Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
Lasater, Elisabeth A., Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Barrett, Kathy, Rys, Ryan N., Oeh, Jason, Lin, Eva, Sterne‐Weiler, Tim, Ingalla, Ellen Rei, Go, MaryAnn, Yu, Shang‐Fan, Krem, Maxwell M., Arthur, Chris, Hahn, Uwe, Johnston, Anna, Karur, Vinit, Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Polson, Andrew G., Chang, YiMeng, Wever, Claudia, Johnson, Nathalie A., Jiang, Yanwen, Hirata, Jamie, Sampath, Deepak, Musick, Lisa, Flowers, Christopher R., Wertz, Ingrid E.
Published in American journal of hematology (01.03.2023)
Published in American journal of hematology (01.03.2023)
Get full text
Journal Article
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin
Campbell, Marcia R., Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N., Ahuja, Deepika, Moasser, Mark M., Park, Catherine C.
Published in Breast cancer research and treatment (01.02.2016)
Published in Breast cancer research and treatment (01.02.2016)
Get full text
Journal Article
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells
Amin, Dhara N., Bielenberg, Diane R., Lifshits, Eugene, Heymach, John V., Klagsbrun, Michael
Published in Microvascular research (01.05.2008)
Published in Microvascular research (01.05.2008)
Get full text
Journal Article
A TORC2-Akt feedforward topology underlies HER3 resiliency in HER2-amplified cancers
Amin, Dhara N., Ahuja, Deepika, Yaswen, Paul, Moasser, Mark M.
Published in Molecular cancer therapeutics (05.10.2015)
Published in Molecular cancer therapeutics (05.10.2015)
Get full text
Journal Article
Abstract 880: Anti-tubulin antibody drug conjugates potentiate venetoclax activity in non-Hodgkin lymphoma by targeting MCL-1
Amin, Dhara N., Oeh, Jason, Zindal, Anuradha, Musick, Lisa, Hirata, Jamie, Mobasher, Mehrdad, Polson, Andy, Sampath, Deepak, Wertz, Ingrid E.
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article
Abstract CT133: Targeting BCL-2 and MCL-1 overcomes treatment resistance in relapsed and refractory non-Hodgkin lymphoma: Pre-clinical rationale and results from an open-label phase 1b study
Amin, Dhara N., Bannerji, Rajat, Mali, Raghuveer Singh, Oeh, Jason, Lin, Eva, Zindal, Anuradha, Go, MaryAnn, Yu, Shang-Fan, Krem, Maxwell, Arthur, Chris, Hahn, Uwe, Johnston, Anna M., Karur, Vinit G., Khan, Nadia, Marlton, Paula, Phillips, Tycel, Gritti, Giuseppe, Seymour, John F., Tani, Monica, Yuen, Sam Yuen, Martin, Scott, Chang, Matthew T., Rose, Christopher M., Pham, Victoria C., Lasater, Elizabeth A., Polson, Andrew G., Chang, YiMeng, Hirata, Jamie, Musick, Lisa, Sampath, Deepak, Flowers, Christopher R., Wertz, Ingrid E.
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Published in Cancer research (Chicago, Ill.) (15.08.2020)
Get full text
Journal Article
Effective treatment of HER2-amplified breast cancer by targeting HER3 and [beta]1 integrin
Campbell, Marcia R, Zhang, Hui, Ziaee, Shabnam, Ruiz-Saenz, Ana, Gulizia, Nathaniel, Oeffinger, Julie, Amin, Dhara N, Ahuja, Deepika, Moasser, Mark M, Park, Catherine C
Published in Breast cancer research and treatment (01.02.2016)
Published in Breast cancer research and treatment (01.02.2016)
Get full text
Journal Article
Abstract 1653: Highly effective treatment of HER2-amplified breast cancers through the complete inactivation of the HER2-HER3 tumorigenic driver
Amin, Dhara N., Sergina, Natalia, Ahuja, Deepika, McMahon, Martin, Wang, Donghui, Hann, Byron, Shokat, Kevan, Moasser, Mark M.
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Published in Cancer research (Chicago, Ill.) (15.04.2010)
Get full text
Journal Article